Abaloparatide Dosage, half-life & reference guide

Also known as Tymlos · BA058

Reviewed 8 studiesEvidence: EstablishedPublished by PepVault

A daily shot (Tymlos) that builds new bone, a close relative of teriparatide modelled on a different natural hormone, PTHrP. In its 18-month trial, new spine fractures fell from 4.2% on placebo to 0.6%, and blood calcium ran high less often than on teriparatide.

FDA label
80 mcgstarting dose 80 mcg
How often
Daily
Half-life
~1 hour
Evidence
●●● Established
Route
SubQ injection

Abaloparatide dose guide

How it works.

A bone-building 34-amino-acid peptide modelled on PTHrP, the parathyroid-hormone-related peptide (76% the same as its active part, 41% the same as teriparatide's PTH). It activates the PTH1 receptor on bone cells, and a daily dose stimulates the bone-building cells, so new bone forms on the inner and outer surfaces. FDA-approved in 2017 for postmenopausal women with osteoporosis at high fracture risk, and later for men; it is the sibling of teriparatide, with one dose and the same 2-year limit.

Commonly reported: Redness where the shot goes in, and dizziness or a fast heartbeat for a while after the first doses. FDA-approved since 2017, for up to 2 years.

Half-life & active level

The half-life of Abaloparatide is ~1 hour (FDA label).

Here's how a typical Abaloparatide schedule plays out over 48 hours (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.

A smiling man in a grey training top on a sofa with a foam roller beside him, his phone in his hands

PepVault for iPhone

Track abaloparatide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where Abaloparatide works.

A body with Joints & tendons lit
  • Joints & tendons

    In people. In its 18-month trial, new spine fractures fell from 4.2% on placebo to 0.6%, and blood calcium ran high less often than on teriparatide.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

Week by week.

What to expect in the first 8 weeks

Onset
1 month (bone formation markers)
Peak effect
12–18 months (BMD, fracture risk)
Duration
Up to 24 months
  1. Day 1–14 · 80 mcgRCT

    The first shots, sitting down

    Abaloparatide has one dose, 80 mcg a day, with no ramp. The label gives the first several shots sitting or lying down: a fast heartbeat or dizziness can come within a few hours and usually settles by lying down.

    The science

    Orthostatic hypotension can occur, typically within 4 hours of injection, with dizziness, palpitations, tachycardia or nausea (Tymlos label §5.3). In its thorough QT study, heart rate rose a mean 15 bpm at 15 minutes after 80 mcg, and the increase resolved in about 6 hours. Dizziness: 10% vs 6% on placebo; palpitations 5% vs 0.4%.

    Sources
    • FDA Tymlos label (2026)

    Updated Nov 2026

  2. Day 14–60RCT

    Redness where the shot goes in

    Redness at the injection spot is the most common thing people notice in the first month; rotating the spot around the navel each day is what the label describes. Severe reactions were rare in its trial.

    The science

    In the first month of the fracture trial, injection-site reactions were checked daily 1 hour after the shot: redness 58% vs 28% on placebo, swelling 11% vs 3%, pain 10% vs 7%; severe redness, swelling and pain in 2.9%, 0.4% and 0.4% (label).

    Sources
    • FDA Tymlos label (2026)

    Updated Nov 2026

  3. Any dayRCT

    What Abaloparatide is built on

    Abaloparatide was approved in 2017 on ACTIVE, an 18-month fracture trial of 2,463 women that also ran teriparatide openly beside it. High blood calcium was less common than on teriparatide; the trial was not built to compare their fracture rates.

    The science

    ACTIVE (Miller 2016) randomised women to blinded abaloparatide 80 mcg or placebo, with an open-label teriparatide 20 mcg arm; the primary end point was abaloparatide vs placebo. Hypercalcemia: 3.4% vs 6.4% on teriparatide. The men's indication rests on Study 019 (label). In rats, osteosarcoma reached 87% of high-dose males; its relevance to people is uncertain.

    Sources
    • Miller et al. (ACTIVE) (2016)
    • FDA Tymlos label (2026)

    Updated Nov 2026

  4. With BPC-157 and TB-500Community

    Why people pair it with BPC-157 or TB-500

    Some people with a bone injury run BPC-157 or TB-500 beside a prescribed bone-building drug, hoping the soft-tissue peptides help the tissue around it. Commonly reported as a pairing; no trial has tested it.

    The science

    Abaloparatide's bone effect is shown in people (Miller 2016); BPC-157's repair research is almost all in animals (Sikiric 2018). No study has combined them.

    Sources
    • Miller et al. (ACTIVE) (2016)
    • Sikiric et al. (2018)

    Updated Nov 2026

After week 8

  1. Day 60–365RCT

    New bone, built in the background

    There's little to feel while it works; the change shows on a bone scan. In its men's trial, spine density rose 8.5% in a year, against 1.2% on placebo.

    The science

    Bone formation marker sPINP peaked at month 1 (93% above baseline in women, 133% in men) and stayed raised (label). In Study 019 (228 men, 12 months), lumbar spine BMD rose 8.5% vs 1.2% on placebo, total hip 2.1% vs under 0.1%, and femoral neck 3.0% vs 0.2%.

    Sources
    • FDA Tymlos label (2026)

    Updated Nov 2026

  2. Day 365–730RCT

    Fewer fractures, then the 2-year line

    In its fracture trial new spine fractures fell by 86% over 18 months. The label doesn't recommend more than 2 years in a lifetime; in the trial, alendronate afterwards kept the lower risk.

    The science

    ACTIVE (Miller 2016): new vertebral fractures 0.6% vs 4.2% on placebo at 18 months (relative risk reduction 86%); nonvertebral fractures 2.7% vs 4.7% (43%). After 18 months, patients moved to alendronate: at 25 months vertebral fractures were 0.6% vs 4.4%, and the reduction held through 24 months of alendronate (label).

    Sources
    • Miller et al. (ACTIVE) (2016)
    • FDA Tymlos label (2026)

    Updated Nov 2026

Day 1 is the day you start it.

FDA Tymlos label (DailyMed, effective August 2026); ACTIVE (Miller 2016). Approved for osteoporosis at high fracture risk in postmenopausal women and men.

Clinical trial data

A typical run.

Run notes

Cycle
The label does not recommend more than 2 years in a lifetime; its fracture trial ran 18 months, followed in the trial by alendronate, which kept the lower fracture risk through 24 more months.Community practice — opinions vary. Not a clinical recommendation.
Timing
Once daily at about the same time, into the abdomen around the navel, rotating the spot each day; the first several doses sitting or lying down (label). Levels peak about 30 minutes after a shot. The pen is refrigerated until first use, then kept at room temperature for up to 30 days.
Route
SubQ injection
Stacks
BPC-157, TB-500

Track it in the app

Safety.

Common side effects

  • Injection site redness
  • Dizziness
  • Nausea
  • Headache
  • Palpitations
  • Fatigue
  • High urine calcium

Interactions

No drug-interaction studies have been done (label). Calcium and vitamin D are added if the diet falls short. No trial has combined it with teriparatide; both act on the same receptor, and each label limits use to about 2 years in a lifetime. Discuss all your medicines with your clinician.

Safety notes

The current Tymlos label has no boxed warning. In a 2-year rat study, osteosarcoma rose with dose at every dose tested (up to 87% of males and 62% of females at the highest, against 0-2% of controls); whether it does so in people is unknown, observational studies of PTH analogs have not shown a raised risk, and data beyond 2 years are limited. The label avoids it in anyone with a raised baseline risk: growing bones, Paget's disease or another bone disease, bone cancer or metastases, or radiation to the skeleton. A drop in blood pressure on standing can come within 4 hours of a shot, with dizziness, a racing heart or nausea, so the first doses are given sitting or lying down; heart rate rose 15 beats per minute on average shortly after a dose and settled within about 6 hours. It can raise blood and urine calcium, so it is not used with a high-calcium disorder. Serious allergic reactions have been reported. These are label findings; review them with your clinician.

Goes with.

Brand-name products.

Questions people ask.

What is Abaloparatide?

A daily shot (Tymlos) that builds new bone, a close relative of teriparatide modelled on a different natural hormone, PTHrP. In its 18-month trial, new spine fractures fell from 4.2% on placebo to 0.6%, and blood calcium ran high less often than on teriparatide.

How is Abaloparatide dosed in research?

The FDA label range for Abaloparatide is 80 mcg, daily SubQ, with a 80 mcg starting dose.

How long does Abaloparatide last?

The half-life of Abaloparatide is ~1 hour (FDA label).

What do people report on Abaloparatide?

Commonly reported on Abaloparatide: redness where the shot goes in, and dizziness or a fast heartbeat for a while after the first doses. FDA-approved since 2017, for up to 2 years.

Is Abaloparatide safe?

The research basis for Abaloparatide is established: clinical trials or FDA-approved use exists. Common side effects in the library: injection site redness, dizziness, nausea, headache, palpitations, fatigue and high urine calcium.

What does Abaloparatide stack with?

Common stacks for Abaloparatide: BPC-157 and TB-500.

Track it in the app

Research.

The literature

Search the latest research

Reference.

Cadence

Daily

Daily SubQ

Half-life

~1 hour

~1 hour (FDA label)

Research basis

●●● Established

Clinical trials or FDA-approved use exists

PepVault for iPhone

Track abaloparatide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo

Reviewed How we check the library